Skip to main content

Table 1 Baseline clinical characteristics of the study patients

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

  COPD
Number 274
Gender, female, n (%) 17 (6.2)
Age, years 72.2 ± 7.9
Smoking Index, pack-years 55.2 ± 29.7
Current smokers, n (%) 26 (9.6)
BMI, kg/m2 22.9 ± 3.1
FEV1/FVC, % 52.4 ± 12.3
% FEV1, % 63.3 ± 21.1
GOLD grade 1/2/3/4, n (%) 63/134/61/16 (23.0/48.9/22.3/5.8)
Baseline CAT score 12.2 ± 8.0
LAMA, n (%) 170 (62.0)
LABA, n (%) 136 (49.6)
ICS, n (%) 93 (33.9)
Dose of ICSa, μg/day, median 500
WBC, n 6208 ± 1566
Neutrophil, % 60.3 ± 8.9
Neutrophil, n 3797 ± 1320
Lymphocyte, % 29.2 ± 8.2
Lymphocyte, n 1770 ± 553
NLR 2.1(1.6–2.7)
Eosinophil, % 3.4 ± 2.6
Eosinophil, n 204 ± 150
  1. Data are shown as mean ± SD and median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, BMI body mass index, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, % FEV 1 ratio of predicted FEV1, GOLD Global Initiative for Chronic Obstructive Lung Disease, CAT COPD assessment test, LAMA long-acting muscarinic antagonist, LABA long-acting β2 agonist, ICS inhaled corticosteroids, WBC white blood cell, NLR Neutrophil-to-Lymphocyte ratio
  3. aDose of inhaled corticosteroid is shown as fluticasone propionate equivalent